Effect of dietary fatty acids on human lipoprotein metabolism: A comprehensive update

Nutrients

Volumn 7, Issue 6, 2015, Pages 4416-4425

  Ooi, Esther M M ^a   Watts, Gerald F ^a,b   Ng, Theodore W K ^a   Barrett, P Hugh R ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cardiovascular disease; Dietary fatty acids; Dyslipidemia; Lipoprotein metabolism

Indexed keywords

APOLIPOPROTEIN E; DOCOSAHEXAENOIC ACID; HIGH DENSITY LIPOPROTEIN; ICOSAPENTAENOIC ACID; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; TRANS FATTY ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID; OMEGA 6 FATTY ACID;

CARDIOVASCULAR RISK; DYSLIPIDEMIA; ENERGY CONVERSION; FAT INTAKE; GENE INTERACTION; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPOLYSIS; LIPOPROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; BLOOD; CARDIOVASCULAR DISEASE; DRUG EFFECTS; LIPID METABOLISM; RISK FACTOR;

APOLIPOPROTEINS E; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; DYSLIPIDEMIAS; FATTY ACIDS; FATTY ACIDS, MONOUNSATURATED; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; LIPID METABOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TRIGLYCERIDES;

EID: 84930960108     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7064416     Document Type: Review

References (29)

1. Millen, B.E.; Wolongevicz, D.M.; de Jesus, J.M.; Nonas, C.A.; Lichtenstein, A.H. 2013 American Heart Association/American College of Cardiology Guideline on lifestyle management to reduce cardiovascular risk: Practice opportunities for registered dietitian nutritionists. J. Acad. Nutr. Diet.2014, 114, 1723–1729
2. Harris, W.S. Are n-3 fatty acids still cardioprotective? Curr. Opin. Clin. Nutr. Metab Care2013, 16, 141–149
3. Mori, T.A. Dietary n-3 PUFA and CVD: A review of the evidence. Proc. Nutr. Soc.2014, 73, 57–64
4. Mozaffarian, D.; Wu, J.H. Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. J. Am. Coll. Cardiol. 2011, 58, 2047–2067
5. Caviglia, J.M.; Gayet, C.; Ota, T.; Hernandez-Ono, A.; Conlon, D.M.; Jiang, H.; Fisher, E.A.; Ginsberg, H.N. Different fatty acids inhibit apoB100 secretion by different pathways: Unique roles for ER stress, ceramide, and autophagy. J. Lipid Res.2011, 52, 1636–1651
6. Ooi, E.M.; Lichtenstein, A.H.; Millar, J.S.; Diffenderfer, M.R.; Lamon-Fava, S.; Rasmussen, H.; Welty, F.K.; Barrett, P.H.; Schaefer, E.J. Effects of Therapeutic Lifestyle Change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects. J. Lipid Res.2012, 53, 1958–1967
7. Levy, E.; Spahis, S.; Ziv, E.; Marette, A.; Elchebly, M.; Lambert, M.; Delvin, E. Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: Impact of dietary n-3 fatty acids. Diabetologia2006, 49, 1937–1945
8. Wong, A.T.; Chan, D.C.; Barrett, P.H.; Adams, L.A.; Watts, G.F. Effect of omega-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: A new tracer kinetic study in the postprandial state. J. Clin. Endocrinol. Metab.2014, 99, E1427–E1435
9. Cottin, S.C.; Sanders, T.A.; Hall, W.L. The differential effects of EPA and DHA on cardiovascular risk factors. Proc. Nutr. Soc.2011, 70, 215–231
10. Mozaffarian, D.; Wu, J.H. (n-3) Fatty acids and cardiovascular health: Are effects of EPA and DHA shared or complementary? J. Nutr. 2012, 142, 614S–625S
11. Bosch, J.; Gerstein, H.C.; Dagenais, G.R.; Diaz, R.; Dyal, L.; Jung, H.; Maggiono, A.P.; Probstfield, J.; Ramachandran, A.; Riddle, M.C.; et al. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N. Engl. J. Med. 2012, 367, 309–318
12. Kromhout, D.; Giltay, E.J.; Geleijnse, J.M. n-3 Fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 2010, 363, 2015–2026
13. Mozaffarian, D.; Marchioli, R.; Macchia, A.; Silletta, M.G.; Ferrazzi, P.; Gardner, T.J.; Latini, R.; Libby, P.; Lombardi, F.; O’Gara, P.T.; et al. Fish oil and postoperative atrial fibrillation: The Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA 2012, 308, 2001–2011
14. Macchia, A.; Grancelli, H.; Varini, S.; Nul, D.; Laffaye, N.; Mariani, J.; Ferrante, D.; Badra, R.; Figal, J.; Ramos, S.; et al. Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation: Results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) Trial. J. Am. Coll. Cardiol. 2013, 61, 463–468
15. Van Schalkwijk, D.B.; Pasman, W.J.; Hendriks, H.F.; Verheij, E.R.; Rubingh, C.M.; van Bochove, K.; Vaes, W.H.; Adiels, M.; Freidig, A.P.; de Graaf, A.A. Dietary medium chain fatty acid supplementation leads to reduced VLDL lipolysis and uptake rates in comparison to linoleic acid supplementation. PLoS ONE 2014, 9, e100376
16. Shepherd, J.; Packard, C.J.; Grundy, S.M.; Yeshurun, D.; Gotto, A.M., Jr.; Taunton, O.D. Effects of saturated and polyunsaturated fat diets on the chemical composition and metabolism of low density lipoproteins in man. J. Lipid Res.1980, 21, 91–99
17. Turner, J.D.; Le, N.A.; Brown, W.V. Effect of changing dietary fat saturation on low-density lipoprotein metabolism in man. Am. J. Physiol.1981, 241, E57–E63
18. Sanders, T.A.; Filippou, A.; Berry, S.E.; Baumgartner, S.; Mensink, R.P. Palmitic acid in the sn-2 position of triacylglycerols acutely influences postprandial lipid metabolism. Am. J. Clin. Nutr.2011, 94, 1433–1441
19. Tremblay, A.J.; Lamarche, B.; Labonte, M.E.; Lepine, M.C.; Lemelin, V.; Couture, P. Dietary medium-chain triglyceride supplementation has no effect on apolipoprotein B-48 and apolipoprotein B-100 kinetics in insulin-resistant men. Am. J. Clin. Nutr.2014, 99, 54–61
20. Zheng, C.; Khoo, C.; Furtado, J.; Ikewaki, K.; Sacks, F.M. Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III. Am. J. Clin. Nutr.2008, 88, 272–281
21. Kien, C.L.; Bunn, J.Y.; Stevens, R.; Bain, J.; Ikayeva, O.; Crain, K.; Koves, T.R.; Muoio, D.M. Dietary intake of palmitate and oleate has broad impact on systemic and tissue lipid profiles in humans. Am. J. Clin. Nutr.2014, 99, 436–445
22. Matthan, N.R.; Welty, F.K.; Barrett, P.H.; Harausz, C.; Dolnikowski, G.G.; Parks, J.S.; Eckel, R.H.; Schaefer, E.J.; Lichtenstein, A.H. Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arterioscler. Thromb. Vasc. Biol.2004, 24, 1092–1097
23. Gayet-Boyer, C.; Tenenhaus-Aziza, F.; Prunet, C.; Marmonier, C.; Malpuech-Brugere, C.; Lamarche, B.; Chardigny, J.M. Is there a linear relationship between the dose of ruminant trans-fatty acids and cardiovascular risk markers in healthy subjects: Results from a systematic review and meta-regression of randomised clinical trials. Br. J. Nutr. 2014, 112, 1914–1922
24. Gebauer, S.K.; Chardigny, J.M.; Jakobsen, M.U.; Lamarche, B.; Lock, A.L.; Proctor, S.D.; Baer, D.J. Effects of ruminant trans fatty acids on cardiovascular disease and cancer: A comprehensive review of epidemiological, clinical, and mechanistic studies. Adv. Nutr. 2011, 2, 332–354
25. Liang, S.; Steffen, L.M.; Steffen, B.T.; Guan, W.; Weir, N.L.; Rich, S.S.; Manichaikul, A.; Vargas, J.D.; Tsai, M.Y. APOE genotype modifies the association between plasma omega-3 fatty acids and plasma lipids in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis2013, 228, 181–187
26. Weisgraber, K.H. Apolipoprotein E distribution among human plasma lipoproteins: Role of the cysteine-arginine interchange at residue 112. J. Lipid Res. 1990, 31, 1503–1511
27. Bradberry, J.C.; Hilleman, D.E. Overview of omega-3 Fatty Acid therapies. P. T.2013, 38, 681–691
28. Mahley, R.W.; Huang, Y.; Weisgraber, K.H. Putting cholesterol in its place: APOE and reverse cholesterol transport. J. Clin. Investig.2006, 116, 1226–1229
29. Ooi, E.M.; Janus, E.D.; Grant, S.J.; Sinclair, L.M.; PH, R.B. Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects. J. Lipid Res. 2010, 51, 2413–2421